The Jackson Laboratory

A key player in providing individualized medicines to patients is industry partners. The N=1 Collaborative Inaugural Annual Meeting 2024 Industry Panel featured Nianwei Lin of iXCells Biotechnologies, David Butler of Hongene Biotech Corporation, Rebecca Miles of ReiNA Consulting, Cat Lutz of The Jackson Laboratory, and Jeremy Little of ChemGenes. Panelists discussed how n-of-1 treatments differ from traditional therapy development in terms of process, scale, and methods. They also identified what they believe is the biggest bottleneck for scaling up and ensuring sustainability in the development of n-of-1 oligonucleotide drugs. Thank you to our industry partners for problem-solving with us to bring individualized therapies to patients in their lifetime. Nianwei Lin David Butler Rebecca Miles Cat Lutz Jeremy Little, Jillian Belgrad, Stefanie Leonard, MSN, RN, Geri Beaty, Annemieke Aartsma-Rus, Nicole Nolen, Erin M. McConnell, Ph.D., Winston Yan, MD PhD, Tim Yu, Julia Vitarello, Hugh Hempel, Holm Graessner, Nicole Boice, Nina Green, Ashley Kuniholm, Margaret Meserve, MS, CGC, Erika Fullwood Augustine, Scott Demarest, Richard Finkel, MD, John Keilty, Marlen Lauffer, Rebecca Schüle, Jonathan Watts, Melody Joy Paine

JAX professor Jeffrey Chuang's recently published study in Communications Biology reveals never-before-seen details of the interactions of cancer cells and their surrounding cells. “Researchers have long suspected that better characterizing this complex community, which includes immune cells, blood vessels, and signaling molecules, could shed light on how cancers grow, spread, and respond to treatment,” said Chuang. "This new analysis lets us quantify the locations and interactions of cells and molecules in a way that has never before been possible using imaging.” Read more: https://lnkd.in/e2RibDzc

JAX professor Gary Churchill, Ph.D. recently spoke with Nick Jikomes, Ph.D on the Mind & Matter Podcast 🧠 about his study published in Nature which explores using the power of genetic diversity in mice to uncover new details about the relationship between diet and longevity. 🎧 👀 Watch & listen to the full episode: https://lnkd.in/eciqpdEv 📖 Read more: https://lnkd.in/ejse86xD

During remarks at a recent New England Council Capitol Hill Report meeting, U.S. Senator Susan Collins recognized The Jackson Laboratory for its work on Alzheimer’s disease research. We are grateful to Senator Collins for her support of our research. JAX scientists are working to improve AD research and open new areas of exploration and discovery. Read more about their latest findings and the work of The Model Organism Development and Evaluation for Late-onset Alzheimer’s Disease (MODEL-AD) Consortium, a multi-institution collaboration established to create and distribute effective mouse models for AD: https://bit.ly/3NIghIm Pictured L-R: JAX Vice President of External and Government Affairs LuAnn Ballesteros, Senator Collins

Today, we remember the tragic events of October 25, 2023, in Lewiston, Maine. Our hearts remain with the families and loved ones of the victims, and we are honored to be part of Maine’s resilient and special community.

JAX researchers Michael Stitzel, Ph.D., and Duygu Ucar, PhD discovered that DNA sequence changes known to increase a person’s risk for diabetes are linked to how well pancreatic cells can handle stress, including inflammation and high blood pressure. Learn more ➡️ the study was published in Cell Metabolism and featured here in Genetic Engineering & Biotechnology News: https://lnkd.in/euVur7Mt

In a new Nature study, a team of researchers at YSM, The Jackson Laboratory, and the Broad Institute of MIT and Harvard use generative #AI to create #DNA sequences never seen in nature. The synthetic sequences, or cis-regulatory elements, can selectively turn #genes “on” and “off” in targeted cell types. https://brnw.ch/21wO2Gq

💡 JAX researchers and colleagues at Broad Institute of MIT and Harvard, and Yale University have used AI to design thousands of new DNA switches that can precisely turn the expression of a gene up or down in just one tissue without affecting the rest of the body. The breakthrough tool could have significant biomedical implications for therapeutic purposes. Read more: https://lnkd.in/gfww6iUj

Dr. Jens Rueter recently spoke at the 2024 State of AI in Precision Health conference about AI's transformative role in precision oncology. He highlighted how AI could revolutionize personalized cancer care by enhancing the analysis of complex genomic data -- improving clinical decision-making and leading to better patient outcomes. Dr. Rueter also emphasized AI's potential to analyze large datasets for predictive insights, stressing the need for strong collaboration between clinicians and AI developers to drive innovation and advance cancer treatment strategies. Watch the full talk here: https://lnkd.in/gry53C22 The Jackson Laboratory Institute for Experiential AI at Northeastern University #SAIPH2024 #AIConference #MCGI2024

Join us for a 2-day virtual symposium on October 28-29 to explore the future of antibody-based therapeutic development. Conventional preclinical models often fail to accurately evaluate antibody-based therapeutics, forcing drug developers to adopt cautious and complex strategies. JAX's cutting-edge humanized models offer a solution that is revolutionizing antibody-based therapeutic development. Hear from industry experts as they showcase how JAX humanized models provide better predictions of biologic drug candidate performance—delivering superior preclinical pharmacokinetic, efficacy, and safety data: https://bit.ly/4gWC8sU #Biopharma #Biotech #Biologics #DrugDevelopment #AntibodyDiscovery